Key Highlights:
- Onc.AI unveils FDA breakthrough-designated Serial CTRS model at ASCO25 with strong validation across real-world and Pfizer clinical trial data.
- Demonstrated early prediction of survival and treatment response in NSCLC using routine CT imaging—outperforming traditional RECIST 1.1.
- Collaborations with Baylor Scott & White, University of Rochester, and Pfizer reinforce clinical readiness of Onc.AI’s radiomic platform.
Reinventing RECIST: How Onc.AI’s Serial CTRS is Transforming Imaging Biomarkers
Onc.AI is redefining how oncology imaging data is interpreted through its deep learning-powered Serial CTRS model. Unveiled at ASCO25, the AI model delivers survival predictions and early non-responder identification using routine CT scans. In validation studies with Pfizer and Baylor Scott & White, the model consistently outperformed RECIST 1.1, the current clinical standard. The breakthrough offers a game-changing advantage in dynamic therapy monitoring and patient stratification.
How Onc.AI Bridges AI and Clinical Practice for NSCLC Therapy Decisions
By delivering real-time prognostic insights, Onc.AI equips medical oncologists with actionable intelligence for early treatment adjustments in late-stage NSCLC. The platform, validated both in real-world datasets and pharma-sponsored trials, is shaping a new frontier in personalized oncology care. Poster presentations at ASCO25 by Dr. Ronan Kelly and Dr. Nicholas Love highlight its clinical relevance in adapting first-line immunotherapy strategies.
Collaborative Data Science Driving Clinical Impact
The strength of Onc.AI’s findings stems from strategic collaborations with Pfizer, Baylor Scott & White, and the University of Rochester Medical Center. From image harmonization to response prediction using deep learning radiomic features, these partnerships emphasize the model’s generalizability and value for both academic and pharmaceutical stakeholders.
Backed by Leading Investors and Cancer Research Institutions
Onc.AI’s innovation is supported by top-tier investors including GSK’s Action Potential VC and MassMutual, along with the National Cancer Institute SBIR program. As the company expands adoption of its FDA-designated Serial CTRS, its impact is accelerating both at the point-of-care and within global oncology clinical development.
By